Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2024

Apr 16, 2024

33148_dirs_2024-04-16_4ce79c44-aa6f-4f31-8559-ccc64346e10b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2024-04-12

Reporting Person: SOUTHWELL DAVID P (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-04-12 Common Stock M 70000 $4.342 Acquired 165160 Direct
2024-04-12 Common Stock S 59716 $24.224 Disposed 105444 Direct
2024-04-12 Common Stock S 10284 $25.156 Disposed 95160 Direct
2024-04-15 Common Stock M 29624 $4.342 Acquired 124784 Direct
2024-04-15 Common Stock S 10000 $24.052 Disposed 114784 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-04-12 Stock Option (Right to Buy) $4.342 M 70000 Disposed 2024-08-28 Common Stock (70000) Direct
2024-04-15 Stock Option (Right to Buy) $4.342 M 29624 Disposed 2024-08-28 Common Stock (29624) Direct

Footnotes

F1: Represents shares received upon exercise of Stock Options, which would otherwise expire in August 2024.

F2: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.87 to $24.68. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.155 to $25.17. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Shares were sold by the Reporting Person in order to cover certain tax obligations.

F5: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.85 to $24.335. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: This option represents a right to purchase a total of 99,624 shares of the Issuer's Common Stock, which became fully vested and exercisable on January 4, 2018.